ScholarWorks@Korea University College of Medicine: Han, Changsu

Detailed Information

Han, Changsu (한창수)

Ansan Hospital (Department of Psychiatry, Ansan Hospital)

Research Area: 우울증의 인지기능저하, 치료저항성 우울증 환자의 디지털헬스 증상관리 및 치료, 디지털 헬스 인지기능 우울증상 측정, Cognitive decline in depression, Comprehensive measurement system of depressive patients, Digital health system for cognitive function and mood symptoms

Tel 02-2626-3131
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Depression:48||schizophrenia:21||Schizophrenia:21||depression:21||Major depressive disorder:13||Antidepressant:11||major depressive disorder:11||Bipolar disorder:11||antidepressant:10||Dementia:9||Anxiety:9||Alzheimer's disease:8||augmentation:8||polymorphism:8||bipolar disorder:7||Elderly:7||aripiprazole:7||Major depression:7||Alzheimer disease:6||BDNF:6||major depression:6||PHQ9:6||Stress:6||haloperidol:5||우울증:5||treatment:5||Psychiatry:5||Standardization:5||Suicidal ideation:5||Depressive disorder:5||Antipsychotics:5||Korea:5||Tolerability:5||clinical trial:4||anxiety:4||efficacy:4||Safety:4||treatment response:4||Resilience:4||tolerability:4||Aripiprazole:4||atypical antipsychotics:4||COVID19:4||diagnosis:4||suicide:4||Polypharmacy:4||Efficacy:4||Gender:4||Augmentation:3||antipsychotics:3||Embitterment:3||paroxetine:3||GRIA1:3||Delirium:3||mild cognitive impairment:3||fibromyalgia:3||CREM:3||Vortioxetine:3||GRIA2:3||GRIA4:3||cognitive function:3||Latelife depression:3||response:3||Mild cognitive impairment:3||Inflammation:3||Polymorphism:3||스트레스:3||Trauma:3||treatmentresistant depression:3||Adolescent:3||Physical activity:3||risperidone:3||Korean:3||Adherence:3||mental health:3||cytokine:3||interferon:2||interleukin:2||undifferentiated somatoform disorder:2||ionotropic:2||irritable bowel syndrome:2||Disaster:2||Antidepressive agents:2||Distress:2||Cognitive function:2||Screening:2||Antipsychotic:2||CREB1:2||antidepressants:2||CREBBP:2||Sex:2||불안:2||Patient Health Questionnaire:2||Patient Health Questionnaire9:2||assessment:2||management:2||Guideline:2||HOMER1:2||EEG:2||우울:2||Sleep efficiency:2||Pharmacogenetics:2||metaanalysis:2||Alzheimer's disease (AD):2||methylphenidate:2||Benefit:2||Adjustment disorder:2||Education:2||biomarker:2||biomarkers:2||Effectiveness:2||mortality:2||Biomarkers:2||brainderived neurotrophic factor:2||Loneliness:2||Suicide:2||nitric oxide:2||Metabolic syndrome:2||Posttraumatic growth:2||Switching:2||Electroencephalography:2||Homocysteine:2||Alzheimer’s disease:2||pain:2||paliperidone palmitate:2||panic disorder:2||TGF:2||Emotional labor:2||Moderator:2||Precision medicine:2||Adolescents:2||Mood disorder:2||Temperament:2||Cytokines:2||personality:2||costeffectiveness:2||Aripiprazole once monthly:2||CACNA1C:2||Escitalopram:2||plasma:2||delirium:2||depot:2||depressive disorder:2||prolactin:2||DS14:2||Deep phenotyping:2||dopamine:2||Asia:2||doses:2||Treatment:2||Family:2||Fatigue:2||Female:2||Neuroinflammation:2||relapse:2||Neuroplasticity:2||Type D personality:2||Normative data:2||Questionnaire:2||Attitude:2||restless legs syndrome:2||epistasis:2||Vilazodone:2||RORA:2||Antidepressants:2||Obesity:2||safety:2||sarcopenia:2||Depressive Disorder:2||scopolamine:2||Women:2||Depressive mood:2||Reliability:2||Workers:2||Antidepressive Agents:2||Korea National Health and Nutrition Examination Survey:2||geriatric psychiatry:2||ZNF804A:2||Residual symptom:2||sertraline:2||Response:2||sexual dysfunction:2||Koreans:2||Depressive symptoms:2||stress:2||suicidal ideation:2||tardive dyskinesia:2||Desvenlafaxine:2||Metaanalysis:2||PTED:2||Immune:1||Income:1||Initial choice:1||Insight:1||Insula:1||Intensive care unit:1||Internalizing problem:1||Internet use time:1||Interpersonal trust:1||Intimamedia thickness:1||Intimate partner violence:1||Investigational antipsychotics:1||Issue:1||Job autonomy:1||Job demandcontrol model:1||Job stress:1||KMMSE:1||KDSQ:1||KGDS:1||KYRBS:1||Korea National Health and Nutrition:1||Korean population:1||Korean version of the Snaith Hamilton Pleasure Scale:1||Korean.:1||Lewy body disease:1||Lexical verbal fluency:1||Life satisfaction:1||Light therapy:1||Long acting injectable antipsychotic:1||Longacting injectable antipsychotic:1||Longacting injectable antipsychotics:1||Longitudinal study:1||MAJOR DEPRESSIVE DISORDER:1||MAPK1:1||MDAS:1||MFN2:1||Major:1||Manganese superoxide dismutase:1||Mania·Left frontal·Meningioma.:1||Measurement based care:1||Mediation:1||Medical comorbidity:1||Medical students:1||Medication:1||Medication Event Monitoring System:1||Medication Satisfaction Questionnaire:1||Memantine:1||Memory:1||Memory disorders:1||Menopause:1||MiniMental State Examination:1||Minor depressive disorder:1||Mirtazapine:1||Mirtazapine, therapeutic use:1||Mitochondrial fusion:1||Mixed specifier:1||Modafinil:1||Monotherapy:1||Mood disorders:1||Mood stabilizers:1||Mortality:1||Multicategory classification:1||Myocardial infarction:1||Ncadherin:1||NMBR:1||NPS:1||NRG1:1||Nationally representative population:1||Negative emotion:1||Network metaanalysis:1||Neurobiology:1||Neurodevelopment:1||Neuropathic pain.:1||Neuropsychiatric inventory:1||Neurotransmission:1||Norms:1||Novel mechanism:1||Novel target:1||OLANZAPINE:1||OPC34712:1||Obesity in elderly:1||Openlabel study:1||Oseltamivir:1||Outpatient visits:1||Over the counter drugs:1||Oxidative/nitrosative stress:1||P300:1||PANSS:1||PBMC:1||PCR:1||PDE7B:1||PHQ15:1||PHQ8:1||PPP3CC:1||PROFILE:1||PSS:1||PSYCHOPHARMACOLOGY:1||PTED selfrating scale:1||Pain:1||Paliperidone:1||Parkinson's disease:1||Paroxetine hydrochloride:1||Paroxetine mesylate:1||Pathological worry:1||Pathophysiology:1||Pathway:1||Patient Health Questionnaire4:1||Perceived stress scale:1||Perpetration:1||Personality:1||Pharmacogenetic testing:1||Pharmacogenomics:1||Pharmacogenomics· Antidepressants· Depresion· Serotonin transporter.:1||Pharmacological Treatment:1||Pharmacological treatment:1||Pharmacotherapy:1||Phase II:1||Plasma:1||Plasma biomarker:1||Plasminogen activator inhibitor 1:1||Polysomnography:1||Positive emotion:1||Positron emission tomography:1||Posttraumatic stress disorder:1||Posttraumatic stress disorders:1||Posttraumatic stress symptoms:1||Postpartum depression:1||Posttraumatic embitterment disorder:1||Posttraumatic stress disorder:1||Posttraurnatic symptoms:1||Power:1||Practice guidelines:1||Premature Ejaculation:1||Premenstrual dysphoric disorder:1||Premenstrual mood changes:1||Premenstrual syndrome:1||Prevalence of Depression:1||Prevention:1||Primary care:1||Primary health care:1||Primary progressive aphasia:1||Prolactin:1||Proteus:1||Psychiatric consultation:1||Psychiatric symptom:1||Psychological tests:1||Psychometrics:1||Psychopathology:1||Psychotic disorders:1||Psychotropic drugs:1||Public sector:1||QT interval prolongation:1||QUETIAPINE:1||Quality evaluation · CONSORT · STROBE · TREND · QUOROM · MOOSE.:1||Questionnaires:1||RATINGSCALE:1||RTPCR:1||Ramelteon:1||Randomized clinical trial:1||Randomizedcontrolled clinical trials:1||Reciprocity:1||Region:1||Rehospitalization:1||Relationship:1||Reliability and validity:1||Remission:1||Reserpine:1||Response affective disorder:1||Restingstate functional connectivity:1||Risk:1||Risk factor:1||Routin practice:1||SIGMAR1:1||SOMALIA:1||SP4:1||SSRI:1||ST8SIA2:1||SUMO1:1||SYN2:1||Schizoaffectivedisorder:1||Schizophrenia Antipsychotic drugnaive Cognitive function Attention Memory function Executive function:1||Schizophrenia.:1||School:1||School mental health:1||Selective Serotonin Reuptake Inhibitor:1||Self concept:1||Selfrated health:1||Serotonin uptake inhibitors:1||Sexual function:1||Sick leave:1||Sickness absence:1||Side effect:1||Sigma1 receptor:1||Signal transduction:1||Single nucleotide polymorphisms:1||Sleep irregularity:1||Social capital:1||Social participation:1||Social support:1||Socioeconomic status:1||Soluble amyloid precursor proteins alpha (sAPP alpha):1||Soluble amyloid precursor proteins beta (sAPP beta):1||Somatoform disorders:1||Spectral power:1||Stess:1||StevenJohnson syndrome:1||Stressors:1||Striatum:1||Subjective wellbeing:1||Subthreshold depression:1||Suicide Risk:1||Suicide prevention:1||Suicide·Neurotrophin·BDNF·Lethality of suicide attempt rating scale·Riskrescue rating.:1||Susceptibility:1||Symptom:1||Symptomatology:1||Symptoms improvement:1||Systematic literature review:1||TAP2:1||TIMP3:1||TREATMENT RESPONSE:1||TXNRD2:1||Tamiflu:1||Tardive dyskinesia:1||Temperament and Character Inventory:1||Testosterone:1||Th17 cell:1||The Jolly Fat hypothesis:1||Tic disorder:1||Tinnitus:1||Tolerance:1||Total sleep time:1||Tourette disorder:1||Traumatic Stress:1||Trauma·Embitterment:1||Treatment Satisfaction Questionnaire for Medication:1||Treatment compliance.:1||Treatment resistant depression:1||TreatmentResistant:1||Triglyceride:1||Tryptophan hydroxylase 2:1||Type D Personality:1||Type D personality(DS14)·Cardiovascular disease·Coronary artery disease.:1||Validity:1||Validity.:1||Vascular dementia:1||Venlafaxine, therapeutic use:1||Victimization:1||Vilazodone hydrochloride:1||Voxelbased morphometry:1||WDR60:1||Webbased medical information:1||Weight:1||Weisman and Worden's riskrescue rating:1||Wisdom therapy:1||WordszzDepression:1||Work hours:1||Workfamily conflict:1||Workplace gender discrimination:1||Worry scale:1||Zebrafish:1||Zolpidem:1||Zonisamide:1||abuse:1||acetylLcarnitine:1||action mechanism:1||acute treatment:1||adolescent:1||adverse effect:1||adverse effects:1||adverse event:1||age:1||age of onset:1||agonist:1||aldehyde dehydrogenase 2:1||alternative pathway:1||alternative treatment:1||amenorrhea:1||amygdala:1||amyloid:1||antagonist:1||antidementia pharmaceuticals:1||antiinflammatory effect:1||antidepressant induced mania:1||antidepressant response:1||antidepressant treatment:1||antipsychotic:1||anxiety disorder:1||anxiety disorders:1||anxiety symptom measure:1||aripiprazole once monthly:1||asenapine:1||association study:1||atherosclerosis:1||atrophy:1||attention deficit disorder with hyperactivity:1||attitude:1||atypical:1||atypical antipsychotic:1||atypical depression:1||bias:1||big data:1||biological:1||blonanserin:1||body composition:1||body mass index:1||botulinum toxin:1||brexpiprazole:1||bupropion:1||bupropion XL:1||cfos:1||carbonic anhydrase II:1||catecholOmethyltransferase gene:1||chronic depression:1||chronicity:1||circadian rhythm:1||clinical characteristics:1||clinical improvement:1||clozapine:1||coadministration:1||cognition:1||cognitive behavior therapy:1||cognitive decline:1||cognitive dysfunction:1||combination:1||combination treatment:1||comorbidity:1||complement factor H:1||complement system:1||compliance:1||connectomics:1||conscripts:1||controversy:1||coronary heart disease:1||correlation:1||curcumin:1||cutoff score:1||default mode network:1||deficit syndrome:1||dehydroepiandrosterone sulfate:1||dementia:1||disaster:1||divalproex sodium:1||donepezil:1||dopamine receptor genes, polymorphism:1||dopamine transporter:1||drug delivery system:1||duration of untreated depression:1||dysbindin gene:1||education:1||effectiveness:1||efficacy and tolerability:1||elder:1||elderly:1||elders:1||electronic health record:1||electronic medical record:1||embitterment:1||emergency preparedness:1||emotional health:1||epidemiology:1||erectile dysfunction:1||estradiol:1||eventrelated potential:1||evidence:1||exposomics:1||extrapyramidal symptoms:1||fMRI:1||facial expression:1||fatigue:1||ferry accident:1||fluoxetine:1||frontotemporal dementia:1||frontoparietal network:1||gene polymorphisms:1||generalized anxiety disorder:1||geriatric depression:1||ginseng:1||glutamate receptor:1||glutamatergic:1||guideline:1||guidelines:1||haplotype:1||health care policy:1||health economics:1||heterosis:1||history:1||horse:1||hypothalamicpituitarygonadal axis:1||iloperidone:1||indirect comparison:1||inflammatory response system:1||informed consent:1||insomnia:1||interleukin12:1||interoceptive exposure:1||intimamedia thickness:1||jockey:1||ketamine:1||knowledge:1||lamotrigine:1||latelife depression:1||leptin gene:1||lethality of suicide attempt:1||lethality of suicide attempt rating scale:1||lexical verbal fluency:1||lithium:1||longacting injectable:1||longacting injectable antipsychotics:1||longacting injectable risperidone:1||longacting injection risperidone:1||longacting injections:1||lurasidone:1||maintenance:1||maintenance treatment:1||major depressive disorders:1||mania:1||mechanism of action:1||memory:1||menopause:1||mental health service:1||mental status schedule:1||methamphetamine:1||mild cognitive impairment (MCI):1||milnacipran:1||mindfulnessbased intervention:1||minocycline:1||mirtazapine:1||misdiagnosis:1||mobile health:1||monoamine:1||monoamine oxidase inhibitor:1||monotherapy:1||mood disorder:1||myocardial infarction:1||needlestick:1||negative life events:1||neurocognitive function:1||neuroprotection:1||neuropsychiatric symptoms:1||neuropsychological testing:1||neuropsychology:1||neurotoxicity:1||neurotransmitter:1||neurotropin3:1||newer antidepressants:1||norepinephrine transporter gene:1||normative data:1||novel antidepressant:1||novel mechanism:1||obesity:1||olanzapine:1||omega3 polyunsaturated fatty acids:1||openlabel:1||outcome:1||paliperidone:1||paraffinoma:1||paroxetine CR:1||paroxetine controlled release:1||paroxetine safety:1||partner:1||pathways to care:1||patient schedule:1||penile paraffinoma:1||penis:1||perceived functioning:1||personalized medicine:1||pharmacogenetics:1||pharmacogenomics:1||pharmacological treatment:1||pharmacometabolomics:1||physiological responses:1||pilot study:1||placebo response:1||polymorphisms:1||positron emission tomography:1||posttraumatic stress disorder:1||predictor:1||pregabalin:1||psychiatric disorder:1||psychiatric status rating scales:1||psychiatric symptom:1||psychological:1||psychological assessment of sexual dysfunction:1||psychology:1||psychometrics:1||psychopharmacology:1||questionnaire:1||quetiapine:1||randomized controlled trial:1||receptor:1||recurrence:1||recurrent depression:1||reduced haloperidol:1||relationship:1||relative deprivation:1||relaxation:1||relaxation therapy:1||reliability:1||remission:1||research domain criteria (RDoC):1||residual symptom:1||restingstate functional connectivity:1||retrospective cohort study:1||reuptake inhibition:1||reversion:1||review:1||risk:1||riskrescue rating scale:1||rs1006737:1||sLORETA:1||satisfaction:1||screen:1||seasonality:1||secondgeneration antipsychotic:1||sedativehypnotics:1||selective 5HT7 serotonin receptor antagonist:1||selective serotonin reuptake inhibitor:1||selective serotonin reuptake inhibitors:1||selegiline:1||selegiline transdermal system (STS, EMSAM (TM)):1||selfquestionnaire:1||selfrecognition:1||sensor:1||sertindole:1||service:1||severity:1||sex hormones:1||sexual abuse:1||sharps injury:1||single nucleotide polymorphism:1||skeletal muscle mass:1||somatic symptoms:1||somatoform disorder:1||survey:1||testosterone:1||the elderly:1||therapeutic implication:1||thyroid hormone:1||time to diagnosis:1||transporter:1||treatment guideline:1||tryptophan hydroxylase:1||unipolar depression:1||validity:1||valproic acid:1||vascular dementia:1||virtual reality:1||visceral obesity:1||vitamin D:1||weight gain:1||wellbeing:1||개념:1||걱정 척도·병적인 걱정·신뢰도·타당도.:1||건강복지:1||공공영역 종사자:1||관해:1||기분장애:1||기준점수:1||독거노인:1||병식:1||사회적 지지:1||산후 우울증:1||상후 울분장애:1||서비스 요구도:1||세로토닌 전달체 유전자 다형성:1||스트레스 자각척도:1||신경생물학:1||신뢰도:1||신체질환:1||약물 순응도·알츠하이머 병·치매:1||약물유전체학·항우울제·기분 장애·세로토닌.:1||약물학적 치료:1||외상후 성장:1||우울증상:1||울분:1||월경전 불쾌장애:1||월경전 증후군:1||월경전기 증상:1||인지 기능.:1||자살·Neurotrophin·BDNF·Lethality of
suicide attempt rating scale·Riskrescue
rating.:1||자살시도자:1||정신과 자문·치료순응도.:1||정신병리:1||정신분열병 항정신병 약물 투여 인지기능 주의력 기억기능 실행기능:1||조현병:1||주요우울장애:1||증상척도:1||지혜치료:1||직무 스트레스:1||청소년:1||초기선택:1||치매:1||치매 척도:1||코로나바이러스:1||타당도:1||트라우마:1||표준화:1||한국형.:1||항우울제:1||3D display:1||항우울제 약물유전체학:1||3DTV:1||5HT1 receptor agonists:1||5HTR1A and GPRIN2:1||ABCB1:1||ABCB4:1||ADHD:1||AHI1:1||AHI1 gene:1||AMPA 2 (GRIA2):1||AMPA 4 (GRIA4):1||ARC:1||ARC gene:1||Abnormal involuntary movements:1||Abuse:1||AcetylLcarnitine:1||Acetylcholinesterase inhibitors:1||Action mechanism:1||Adipokine:1||Adiposity in elderly:1||Adjunctive treatment:1||Age:1||Age Differences:1||Agomelatine:1||Alzheimer:1||Alzheimer's:1||Alzheimer?s dementia:1||Amnestic mild cognitive impairment (aMCI):1||Amyloid:1||Amyloid accumulation:1||Anhedonia:1||Animal model:1||Antipsychotic Agents:1||Antisperm antibody:1||Anxiety disorders:1||Anxious depression:1||Approach:1||Aripiprazole augmentation:1||Asiapacific:1||Association study:1||Atherosclerotic plaque:1||Atypical antipsychotics:1||BDI:1||BDV:1||BIPOLAR DISORDER:1||Behavioral and psychological symptoms of dementia:1||Behavioral rating scale:1||Big data:1||Bipolardisorders:1||Borna disease virus:1||Brain:1||Brainderived neurotrophic factor:1||Brandname product:1||Brief resilience scale:1||Bupropion:1||CARE:1||CHL1:1||CHRNA7:1||CLINICAL IMPROVEMENT:1||CLOCK:1||COMT:1||CONSORT statement:1||CONSORT·STROBE·TREND·QUOROM· MOOSE.:1||CPLX1:1||CPLX2:1||CREB:1||CSKGDS:1||CSF:1||CUDOS:1||Calcium channel:1||Carbamazepine:1||Carnitine:1||Carotid arteries:1||Carotid intimamedia thickness:1||Carotid plaque:1||Cation transmembrane transporter:1||Cerebrospinal fluid:1||Character:1||Chemokines:1||Children:1||Children and adolescents:1||Cholinesterase inhibitors:1||Chronic disease:1||Citalopram:1||Classifying:1||Clinical Trial:1||Clinical benefit:1||Clinical trial:1||Clinical utility:1||Cognitive complaint:1||Cognitive dysfunction:1||Cognitive impairment:1||Coherence:1||Combination:1||Comparative study:1||Complex regional pain syndrome:1||Computerassisted signal processing:1||Conception:1||Consensus:1||Controlledreleasedrugs:1||Coronary Disease:1||Cutoff point:1||Cutoff score:1||Cytokine:1||Cytokine weighted score:1||DAMINO ACID OXIDASE ACTIVATOR (DAOA):1||DAOA:1||DRD2:1||DRS:1||Definition:1||Dementia of Lewy body:1||Dementia scale:1||Dementia, prevalence:1||Dependence:1||Depresion· Schizophrenia· CDSS· KCDS· Standardization.:1||Depression care:1||Depressive symptom:1||Dexmedetomidine:1||Digit length ratio:1||Disinhibition:1||Dopamine receptor D2:1||Drug adherence:1||Drug implant:1||Drugrelated Side Effects and Adverse Reactions:1||D형 인격·DS14·심혈관 질환·관상동맥질환:1||ELISA:1||EPM2A:1||ESYT2:1||Economic problem:1||Effects:1||Elders:1||Electroconvulsive therapy:1||Electronic health records:1||Emotional demand:1||Emotional problems:1||Emotional social support:1||Employees:1||Employees.:1||Enuresis:1||Epistasis:1||Examination Survey:1||Experimental model.:1||Expert panel:1||Eye movement desensitization reprocessing:1||FetuinA:1||Fibromyalgia:1||Firstnight effect:1||Fluoxetine:1||Folate:1||Frequency:1||G protein:1||Gprotein:1||GBS scale:1||GBS 척도:1||GDS15:1||GNB3:1||GWAS:1||Gene:1||General Population:1||General working population:1||Generalized anxiety disorder:1||Generic:1||Genetic:1||Genetics:1||Geriatric Depression:1||Glucose:1||Glutamate receptor:1||Glutamate receptors:1||HTR2A:1||Handgrip strength:1||Happiness:1||Harm avoidance:1||Health:1||Health Insurance Review and Assessment Service Data:1||Health care surveys:1||Health care utilization:1||Health insurance:1||Health risk behaviors:1||Healthcare workers:1||Heart:1||Highsensitivity Creactive protein:1||Human influenza:1||Hybrid Model:1||Hypertension:1||Hypoxic brain damage:1||IESRK:1||IL17:1||IL23:1||IL8:1||INTERVENTION:1||

STATISTICS: Total View :12,637,823; Today View :3,936

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE